In order to draw a more precise conclusion and support the use of GSTT1 as an additional genetic biomarker for predicting the risk of ATDILI in TB patients, further studies are warranted to investigate multi-genetic effects including NAT2, CYP2E1, and GSTs genetic polymorphisms on the risk of ATDILI. This evidence concerns the gene NAT2 and tuberculosis.